Lb Pharmaceuticals (LBRX) Common Equity (2024 - 2026)

Lb Pharmaceuticals' Common Equity history runs 3 years deep, the most recent figure standing at $378.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 481.22% year-over-year to $378.7 million; the TTM figure through Mar 2026 stood at $378.7 million (up 481.22% YoY), while the FY2025 annual figure was $301.3 million, up 418.66% from the prior year.
• Common Equity was $378.7 million for Q1 2026 at Lb Pharmaceuticals, up from $301.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $378.7 million in Q1 2026 to a low of -$99.3 million in Q1 2025.
• Historically, Common Equity has averaged $117.5 million across 3 years, with a median of $104.9 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Common Equity surged 418.66% in 2025, then soared 481.22% in 2026.
• A 3-year view of Common Equity shows it stood at -$94.6 million in 2024, then soared by 418.66% to $301.3 million in 2025, then rose by 25.68% to $378.7 million in 2026.
• The last three Common Equity figures came in at $378.7 million (Q1 2026), $301.3 million (Q4 2025), and $310.2 million (Q3 2025), per Business Quant data.